Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shennon Biotechnologies Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's current prosecution involves a distinct examiner and a distinct art unit. The use of a distinct art unit suggests a narrow technical scope for the pending matters, likely focusing on a specific biological or pharmaceutical advancement. This centralized approach to prosecution allows for a clear focus on a set of examination standards and technical requirements.
EMILY ANN CORDAS is the busiest examiner for the company, managing 1 pending office action. This examiner is responsible for the company's active office actions at this time. With a pending office action, the company's current patent office activity is limited in volume. The progress of the company's intellectual property strategy in this technology area is currently dependent on the resolution of this action by the assigned examiner. Practitioners should focus on addressing the specific technical rejections that often arise in this complex technology area to secure favorable outcomes.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORDAS, EMILY ANN | 1 | 50.8% | +57.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18503723 | Microfluidic Devices for High Throughput Screening of Cell-Cell Interactions | CORDAS, EMILY ANN | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18503723 | Microfluidic Devices for High Throughput Screening of Cell-Cell Interactions | CORDAS, EMILY ANN | 1632 | §102§103§112DP | Non-Final OA | — | Pending | Nov 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial